Global Blood reports Phase III sickle cell data that could support accelerated approval of voxelotor

Global Blood Therapeutics Inc. (NASDAQ:GBT) reported data from Part A of the Phase III HOPE trial that it believes could support accelerated approval of voxelotor (formerly GBT440) to treat sickle cell disease.

The company said voxelotor met Part A's primary endpoint of improving the proportion of patients with an increase in hemoglobin of more than 1 g/dL from baseline to week 12 vs. placebo. Low- and high-dose voxelotor led to hemoglobin responses in 38% (p=0.0021) and 58% (p<0.0001) of patients, respectively, vs. 9% of patients receiving placebo. Each treatment group surpassed the 35% efficacy benchmark Global Blood and FDA had agreed upon, the company said...